PD-1 and PD-L1 Inhibitors Competitive Landscape, Pipeline and Market Analysis Research Report 2017

Researchmoz added Most up-to-date research on "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017" to its huge collection of research reports.

DelveInsights, PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.

This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsights Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=964541

Scope
The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors
The report provides the marketed drugs information including its sales, development activities and details of patent expiry
The report provides the insight of current and future market for PD and PD-L1 inhibitors
The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling
The report also gives the information of dormant pipeline projects

Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
Complete MOA intelligence and complete understanding over therapeutics development for PD-1 and PD-L1 Inhibitors
Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.

Devise corrective measures for pipeline projects by understanding PD-1 and PD-L1 Inhibitors pipeline depth and focus of Indication therapeutics
Developing strategic initiatives to support your drug development activities.

Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=964541

New Release | PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Industry Analysis, 2016

Researchmoz added Most up-to-date research on "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2016" to its huge collection of research reports.

DelveInsight Report, “PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2016” gives the comprehensive insights on the PD-1 and PDl-1 Inhibitors. The report has provided the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors including information of Marketed molecules, detailed profiling of Pipeline assets and their pathways. The report has covered the therapeutics assessment of pipeline molecules by mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates. Report is also dealing with detailed epidemiology of all prevalent indications.

Report has also covered other Commercial Aspects such as the Current and Future Market, Barriers and challenges, SWOT analysis. Report has described the unmet needs covered by PD-1 and PD-L1 inhibitors and highlighted the side effects and toxic effects related to PD-1 and PD-L1 inhibitors which are major concerns in the market for the usage of PD-1 and PD-L1 inhibitors.

The report has also thrown light on the combinations therapies with Immune-check point Inhibitors (PD-1 and PDL-1), provided the information of ongoing collaborations for the development of combinations regimens.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=556851

DelveInsight Analysis predicts that PD-1 and PD-L1 inhibitors are among the highly growing fields in biopharmaceutical industry. Most of these
immunotherapeutic are being used in Oncology. There are 51 drugs are in pipeline with approximate 245 active clinical studies. Companies have also gone in collaboration with different partners like Bristol, Merck, Astrazeneca and Roche for evaluating their drugs in combination with Immune Checkpoint Inhibitors (PD-1/PD-L1). There are total 37 companies found which have partnered with various Big Pharmas.

Out of 51 drugs, 44 drugs are in Monotherapy and 7 drugs are in the combination therapy. Out of 43 Monotherapy drugs, 2 is in Filed stage and 3 drugs are in phase III, 2 drug is in Phase II, 9 drugs are in Phase I, 19 drugs are in Pre-Clinical and 7 drugs are in discovery phase and 2 in Unknown stage. Out of 7 combination therapy drugs 2 are in Phase I, 2 are in Pre-Clinical stage of development and 3 are in Discovery stage.

Future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. There are 3 marketed products of PD-1 and PD-L1 inhibitors. Treatment options such as surgery, chemotherapy, radiation therapy, and many others are able to fulfill the current unmet need to an extent. The market for PD-1 and PD-L1 drugs might be billions of dollars in coming years. These drugs which include Bristol-Myers' Opdivo, Merck's Keytruda and Hoffmann-La Roche' Tecentriq are going to be the blockbuster molecules in upcoming years.

PD-1 and PD-L-1 inhibitors are showing greater efficacy as immune-therapeutic drugs but with the immune system unchecked, there is the possibility that immune cells attack other parts of the body, causing serious problems in the intestines, liver, nerves, eyes, or other organs. Although Preliminary data suggests that PD-1/PD-L1 immunotherapies provide faster and more frequent responses.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=556851